Wegovy injections are FDA approved for adults and children 12 years and older with a body mass index of 30 or more, or patients with additional conditions, such as high cholesterol, hypertension, sleep apnea, type 2 diabetes, heart disease, or other chronic metabolic illnesses, who have body mass index of 27 or more
It can be used as both injection-type or oral-type drug.[9] The marketing authorization in EU was granted on 8 February 2018.[10] It is still under review by regulatory authorities in Japan, pending approval.[11] ------------------------------------- Reported by Jules Levin AASLD 2018 Nov 9-13 SF Philip N Newsome1 ,2, Stephen A Harrison3, Sren Rasmussen4, Tea Monk Fries4, Luc Van Gaal5 1National Institute for Health Research Birmingham Biomedical Research Centre and Liver Unit at University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
The properties that make GHK-Cu effective in improving skin appearance such as stimulating collagen production and supporting cellular health also contribute to its positive impact on hair growth [3, 4]
Findings suggest this interaction may trigger signal cascades involving second messengers such as cAMP, leading to downstream transcriptional activity related to GH synthesis
These effects typically resolve within the first week as the body adapts
Most GLP-1RAs are administered via subcutaneous injections, although oral semaglutide is available
